Vaccine containing whole killed herpes viruses to prevent development of atherosclerotic plaque
AssigneeBio-Virus Research Incorporated
InventorsDaniel Golubev, Alexander Chaihorsky
Life of this patent
Estimating the term…
Abstract
A vaccine is disclosed for the prophylaxis against pathogenic development of atherosclerotic plaque in a mammalian subject susceptible thereto which consists essentially of a multiplicity of killed whole-virus strains, selected from the group consisting of: Herpes Simplex Virus 1; Herpes Simplex Virus 2; Herpes Simplex Virus 6; Human Cytomegalovirus; and Epstein-Barr Virus; in combination with a pharmaceutically acceptable inert vaccine carrier or diluent.
Claims2
A killed whole-virus vaccine pharmaceutical composition for preventing pathogenic development of atherosclerotic plaque, which consists essentially of the following strains in an amount effective to prevent atherosclerotic plaque development:
- Herpes Simplex Virus 1;
- Herpes Simplex Virus 2;
- Herpes Simplex Virus 6;
- Human Cytomegalovirus;
- and
- Epstein-Barr Virus;
- in combination with a pharmaceutically acceptable inert vaccine carrier or diluent.
A method of preventing pathogenic development of atherosclerotic plaque in a mammalian subject susceptible thereto, comprising the step of administering to said mammalian subject, a therapeutically effective amount of a killed whole-virus vaccine pharmaceutical composition which consists essentially of the following strains:
- Herpes Simplex Virus 1;
- Herpes Simplex Virus 2;
- Herpes Simplex Virus 6;
- Human Cytomegalovirus;
- and
- Epstein-Barr Virus;
- in combination with a pharmaceutically acceptable inert vaccine carrier or diluent.
Dependencies are inferred from the claim text.